Pharmaceutical formulation comprising a coated tablet

EP4757782A1Pending Publication Date: 2026-06-17F HOFFMANN LA ROCHE & CO AG +1

Patent Information

Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
F HOFFMANN LA ROCHE & CO AG
Filing Date
2024-08-09
Publication Date
2026-06-17

AI Technical Summary

Technical Problem

Current formulations of GDC-0077 (INAVOLISIB) lack stability, particularly against light degradation, which affects its efficacy and longevity.

Method used

A pharmaceutical formulation comprising a therapeutically effective amount of GDC-0077 (INAVOLISIB) in a solid dosage form with a colored coating, which provides improved light stability and protection against physical and chemical degradation.

Benefits of technology

The formulation enhances the light stability of GDC-0077 (INAVOLISIB), minimizing degradation and maintaining the active ingredient's potency, while also improving manufacturability and reducing costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure EP2024072652_20022025_PF_FP_ABST
    Figure EP2024072652_20022025_PF_FP_ABST
Patent Text Reader

Abstract

The invention relates to pharmaceutical formulation in form of a pharmaceutical formulation comprising GDC-0077 (INAVOLISIB) or a salt thereof, the formulation having a colored coating.
Need to check novelty before this filing date? Find Prior Art